We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme Doses First Patient in Phase II Mesothelioma Study
Read MoreHide Full Article
Epizyme, Inc. announced that it has dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
The study will first evaluate the safety and pharmacokinetic profile of the candidate in patients (n=12) with relapsed or refractory mesothelioma, regardless of BAP1 status. This will be followed by a two-stage study in patients (n=55) with relapsed or refractory mesothelioma characterized by BAP1 loss-of-function.
As per the company’s press release, about 12,000 individuals are affected by mesothelioma each year in the major markets. Out of this, 40–60% of individuals have tumors characterized by BAP1 loss-of-function. Median overall survival for patients with mesothelioma ranges from 8 to 14 months from the time of diagnosis.
We note that the most commonly used first-line treatment for mesothelioma is Eli Lilly and Company’s (LLY - Free Report) Alimta (approved in 2004 for mesothelioma1), used in combination with cisplatin or carboplatin.
We remind investors that Epizyme is currently evaluating tazemetostat in a phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, in a phase II study in adults and in a phase I study in children with certain genetically-defined solid tumors, including INI1-negative or SMARCA4-negative rhabdoid tumors, renal medullary carcinoma, epithelioid sarcoma, other INI1-negative tumors and synovial sarcoma.
Moreover, a couple of combination studies on tazemetostat are expected to begin in 2016. Under a collaboration agreement with Roche Holding AG’s (RHHBY - Free Report) Genentech, Epizyme will evaluate tazemetostat, in combination with Tecentriq (atezolizumab), for the treatment of patients with diffuse large B-cell lymphoma. The company will also evaluate the candidate in combination with R-CHOP for the same indication, in collaboration with the Lymphoma Study Association.
Meanwhile, Aduro BioTech, Inc. is currently evaluating its immunotherapy candidate, CRS-207, in combination with Alimta and cisplatin, as the front-line treatment for patients with unresectable malignant pleural mesothelioma.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Epizyme Doses First Patient in Phase II Mesothelioma Study
Epizyme, Inc. announced that it has dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
The study will first evaluate the safety and pharmacokinetic profile of the candidate in patients (n=12) with relapsed or refractory mesothelioma, regardless of BAP1 status. This will be followed by a two-stage study in patients (n=55) with relapsed or refractory mesothelioma characterized by BAP1 loss-of-function.
As per the company’s press release, about 12,000 individuals are affected by mesothelioma each year in the major markets. Out of this, 40–60% of individuals have tumors characterized by BAP1 loss-of-function. Median overall survival for patients with mesothelioma ranges from 8 to 14 months from the time of diagnosis.
We note that the most commonly used first-line treatment for mesothelioma is Eli Lilly and Company’s (LLY - Free Report) Alimta (approved in 2004 for mesothelioma1), used in combination with cisplatin or carboplatin.
EPIZYME INC Price
EPIZYME INC Price | EPIZYME INC Quote
We remind investors that Epizyme is currently evaluating tazemetostat in a phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, in a phase II study in adults and in a phase I study in children with certain genetically-defined solid tumors, including INI1-negative or SMARCA4-negative rhabdoid tumors, renal medullary carcinoma, epithelioid sarcoma, other INI1-negative tumors and synovial sarcoma.
Moreover, a couple of combination studies on tazemetostat are expected to begin in 2016. Under a collaboration agreement with Roche Holding AG’s (RHHBY - Free Report) Genentech, Epizyme will evaluate tazemetostat, in combination with Tecentriq (atezolizumab), for the treatment of patients with diffuse large B-cell lymphoma. The company will also evaluate the candidate in combination with R-CHOP for the same indication, in collaboration with the Lymphoma Study Association.
Meanwhile, Aduro BioTech, Inc. is currently evaluating its immunotherapy candidate, CRS-207, in combination with Alimta and cisplatin, as the front-line treatment for patients with unresectable malignant pleural mesothelioma.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>